- President Joe Biden will meet his goal of vaccinating 100 million Americans before his 100th day in office, according to Dr. Scott Gottlieb.
- Earlier Wednesday Biden announced plans to buy another 100 million doses of Johnson & Johnson’s single-shot vaccine, bringing the total supply up enough to vaccinate every American.
- Gottlieb said that he thinks “the bigger issue” will be when demand drops off.
President Joe Biden will meet his goal of vaccinating 100 million Americans in his first 100 days in office early, according to Dr. Scott Gottlieb.
"We'll get 100 million Americans vaccinated probably by early April," Gottlieb, who was FDA chief during the Trump administration, predicted. Biden's 100th day in office is April 30.
Get Tri-state area news and weather forecasts to your inbox. Sign up for NBC New York newsletters.
While there is currently not enough supply of Covid vaccines to meet demand, the nation will soon have the exact opposite problem. Earlier Wednesday, Biden announced plans to buy another 100 million doses of Johnson & Johnson's single-shot vaccine. Added to the doses from Pfizer and Moderna, it is more than enough supply to vaccinate every American.
Gottlieb said that he thinks "the bigger issue" will be when demand drops off. In order to stimulate demand in the U.S., he told CNBC's "The News with Shepard Smith," officials must make the vaccine "more accessible," and that includes running clinics where people don't have to sign-up for a vaccine ahead of time.
Nearly 33 million Americans are now fully vaccinated, that's roughly 13% of all U.S. adults, according to the Centers for Disease Control and Prevention. The agency released new guidance Monday for those vaccinated Americans, but Gottlieb told host Shepard Smith that the guidance is too narrow.
"I think we need to prescribe a pathway forward, where people can start to resume their normal lives safely, and give people guidance to do that, and not be so prescriptive," Gottlieb said.
Disclosure: Scott Gottlieb is a CNBC contributor and is a member of the boards of Pfizer, genetic testing start-up Tempus, health-care tech company Aetion Inc. and biotech company Illumina. He also serves as co-chair of Norwegian Cruise Line Holdings' and Royal Caribbean's "Healthy Sail Panel."